This has been used successfully to generate CD229 binders with reduced affinity that yield CARs that can better distinguish multiple myeloma cells from healthy lymphocytes that also express CD229, albeit at a much lower level [171]. The gene discussed is LY9; the disease is plasma cell myeloma.